Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
01:00am, Friday, 01'st Apr 2022
BREDA, the Netherlands--(BUSINESS WIRE)--argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
argenx announces full exercise of underwriters’ option to purchase additional ADSs
09:00pm, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Regulated information — Inside information
argenx announces Annual General Meeting of Shareholders on May 10, 2022
08:30pm, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
March 29, 2022
argenx announces closing of global offering
08:30pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
Regulated information
argenx raises $700 million in gross proceeds in a global offering
01:00am, Thursday, 24'th Mar 2022 GlobeNewswire Inc.
Regulated information — Inside information
argenx (ARGX) Up on Positive Autoimmune Disorder Study Data
12:42pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.
argenx (ARGX) Up on Positive Autoimmune Disorder Study Data
09:47am, Wednesday, 23'rd Mar 2022
argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.
argenx announces launch of proposed global offering
08:15pm, Tuesday, 22'nd Mar 2022 GlobeNewswire Inc.
Regulated information — Inside information
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
07:44pm, Tuesday, 22'nd Mar 2022 Benzinga
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-CO
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx
03:58pm, Tuesday, 22'nd Mar 2022
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-CO
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
12:31pm, Tuesday, 22'nd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Merck's Keytruda Monotherapy Approved For A Type Of Endometrial Cancer
Merck & Co., Inc. (NYSE: MRK) s
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder
12:30pm, Tuesday, 22'nd Mar 2022
Argenx SE (NASDAQ: ARGX) ) has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod for generalized myasthenia gravis (gMG). Myasthenia gravis is a chr
What 8 Analyst Ratings Have To Say About argenx
04:02pm, Monday, 07'th Mar 2022 Benzinga
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
4
0
0
Last 30D
0
0
1
argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
05:50am, Monday, 07'th Mar 2022 Seeking Alpha
argenx SE appears to be a logical buy preference now for investors seeking near-term capital gain. Read more to see why.
